A phase II, multicentre, open labelled randomised control trial to describe immune and transcriptomic responses to trivalent inactivated vaccine (TIV) and MF59 adjuvanted influenza vaccine (ATIV) in 14 - 26 month healthy children

Trial Profile

A phase II, multicentre, open labelled randomised control trial to describe immune and transcriptomic responses to trivalent inactivated vaccine (TIV) and MF59 adjuvanted influenza vaccine (ATIV) in 14 - 26 month healthy children

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ADITEC FLU
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 28 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 10 Jan 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top